Boston Scientific Slumps 2.77 as Regulatory Scrutiny and Cost-Cutting Pressures Weigh on Medical Device Giant With $1.21B Volume Ranking 62nd

On September 15, 2025, , , . The stock’s performance reflected a mix of sector-specific pressures and broader market dynamics, as investors digested recent developments tied to the medical device manufacturer.

Recent regulatory scrutiny in the healthcare sector weighed on investor sentiment, with analysts noting heightened caution around companies facing potential compliance adjustments. While no direct regulatory actions against Boston Scientific were disclosed, industry-wide volatility created a risk-averse environment. Additionally, , a key revenue driver for the company.

Operational updates from Boston Scientific emphasized progress in its R&D pipeline, particularly in . However, . , though the company’s diversified product portfolio remains a structural advantage. , , .

I understand the strategy you have in mind: Each trading day, rank all listed U.S. stocks by that day’s dollar trading volume. Buy (equal-weight) the top 500 names at that day’s close (or open), then liquidate the position at the next day’s close (holding period = 1 trading day). Back-test this from 1 Jan 2022 through the most recent available date. Because this is a cross-sectional, multi-asset strategy, we need two additional pieces of information before I can start assembling the data-retrieval plan: 1. Trading universe – Do you want to rank the entire U.S. listed universe (≈ 8,000 tickers), or a narrower set such as the Russell 3000 or S&P 500 constituents? 2. Execution price – Buy at that day’s CLOSE and sell at the next day’s CLOSE (the industry default for “hold 1 day”)? Or buy at the OPEN and sell at the next day’s OPEN? Please let me know your preference on those two points. Once clarified, I’ll generate the detailed data-retrieval plan and begin the back-test.